Mark A. Clementz

1.1k total citations
10 papers, 895 citations indexed

About

Mark A. Clementz is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, Mark A. Clementz has authored 10 papers receiving a total of 895 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Infectious Diseases and 6 papers in Virology. Recurrent topics in Mark A. Clementz's work include HIV Research and Treatment (6 papers), RNA Research and Splicing (5 papers) and HIV/AIDS drug development and treatment (4 papers). Mark A. Clementz is often cited by papers focused on HIV Research and Treatment (6 papers), RNA Research and Splicing (5 papers) and HIV/AIDS drug development and treatment (4 papers). Mark A. Clementz collaborates with scholars based in United States, France and China. Mark A. Clementz's co-authors include Susan C. Baker, Zhongbin Chen, Li Sun, Bridget S. Banach, Kui Li, Guillaume Mousseau, Daniel Brian Nichols, Yu-Dong Yang, Yaling Xing and Yang Zheng and has published in prestigious journals such as PLoS ONE, Journal of Virology and The FASEB Journal.

In The Last Decade

Mark A. Clementz

10 papers receiving 882 citations

Peers

Mark A. Clementz
Andrew J. Piefer United States
Yosef Sabo United States
Khalid Amine Timani United States
Sarah van Tol United States
Sudip Khadka United States
Szu‐Yuan Pu United States
Ian A. Wilson United States
Andrew J. Piefer United States
Mark A. Clementz
Citations per year, relative to Mark A. Clementz Mark A. Clementz (= 1×) peers Andrew J. Piefer

Countries citing papers authored by Mark A. Clementz

Since Specialization
Citations

This map shows the geographic impact of Mark A. Clementz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Clementz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Clementz more than expected).

Fields of papers citing papers by Mark A. Clementz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Clementz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Clementz. The network helps show where Mark A. Clementz may publish in the future.

Co-authorship network of co-authors of Mark A. Clementz

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Clementz. A scholar is included among the top collaborators of Mark A. Clementz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Clementz. Mark A. Clementz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Mousseau, Guillaume, Rachna Aneja, Mark A. Clementz, et al.. (2019). Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription. mBio. 10(4). 33 indexed citations
2.
Mediouni, Sonia, Krishna Chinthalapudi, Joseph Jablonski, et al.. (2019). Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat. mBio. 10(1). 67 indexed citations
3.
Mediouni, Sonia, Cari F. Kessing, Joseph Jablonski, et al.. (2019). The Tat inhibitor didehydro‐cortistatin A suppresses SIV replication and reactivation. The FASEB Journal. 33(7). 8280–8293. 19 indexed citations
4.
Mediouni, Sonia, Joseph Jablonski, Jason J. Paris, et al.. (2015). Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice. Current HIV Research. 13(1). 64–79. 62 indexed citations
5.
Jablonski, Joseph, Mark A. Clementz, Kevin Ryan, & Susana T. Valente. (2014). Analysis of RNA Processing Reactions Using Cell Free Systems: 3' End Cleavage of Pre-mRNA Substrates <em>in vitro</em>. Journal of Visualized Experiments. 1 indexed citations
6.
Sun, Li, Yaling Xing, Xiaojuan Chen, et al.. (2012). Coronavirus Papain-like Proteases Negatively Regulate Antiviral Innate Immune Response through Disruption of STING-Mediated Signaling. PLoS ONE. 7(2). e30802–e30802. 227 indexed citations
7.
Mousseau, Guillaume, Mark A. Clementz, Wendy Bakeman, et al.. (2012). An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription. Cell Host & Microbe. 12(1). 97–108. 159 indexed citations
8.
Mousseau, Guillaume, Mark A. Clementz, Wendy Bakeman, et al.. (2012). Potent suppression of HIV viral replication by a novel inhibitor of Tat. Retrovirology. 9(S1). 1 indexed citations
9.
Clementz, Mark A., Zhongbin Chen, Bridget S. Banach, et al.. (2010). Deubiquitinating and Interferon Antagonism Activities of Coronavirus Papain-Like Proteases. Journal of Virology. 84(9). 4619–4629. 256 indexed citations
10.
Clementz, Mark A., Amornrat Kanjanahaluethai, Timothy E. O’Brien, & Susan C. Baker. (2008). Mutation in murine coronavirus replication protein nsp4 alters assembly of double membrane vesicles. Virology. 375(1). 118–129. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026